Antimetabolites and cancer: Emerging data with a focus on antifolates

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 2, 2006, Pages 189-200

  Scagliotti, Giorgio V ^a   Selvaggi, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

5 fluorouracil (5 FU); Antifolate; Antimetabolite; Cancer; Gemcitabine; Methotrexate; Pemetrexed; Raltitrexed

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE; ANTIMETABOLITE; BGC 9331; CAPECITABINE; CARBOPLATIN; CISPLATIN; CLOFARABINE; CYANOCOBALAMIN; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; GADOLINIUM TEXAPHYRIN; GEMCITABINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; OXALIPLATIN; PEMETREXED; PENICILLIN G; PLEVITREXED; RALTITREXED; RECOMBINANT COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE INHIBITOR; TRIMETREXATE; UNINDEXED DRUG; VINCA ALKALOID;

ADULT RESPIRATORY DISTRESS SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; BLADDER CANCER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER; CARDIOVASCULAR DISEASE; CEREBELLAR ATAXIA; CLINICAL TRIAL; DIARRHEA; DNA SYNTHESIS INHIBITION; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG SELECTIVITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INFECTION; LIVER INJURY; LUNG INJURY; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; REVIEW; SKIN DISEASE; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA;

EID: 33144484890     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.2.189     Document Type: Review

References (78)

1. FARBER S, DIAMOND LK, MERCER RD, SYLVESTER RF, WOLFF JA: Temporary remission in acute leukaemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). N. Engl. J. Med. (1948) 238:787-789.
2. KPAJINOVIC M, MOGHRABI A: Pharmacogenetics of methotrexate. Pharmacogenomics (2004) 5:819-834.
3. CHU E, DRAKE JC, BOARMAN D, BARAM J, ALLEGRA CJ: Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells. J. Biol. Chem. (1990) 265(15):8470-8478.
4. FISKERSTRAND T, UELAND PM, REFSUM H: Folate depletion induced by methotrexate affects methionine synthase activity and its susceptibility to inactivation by nitrous oxide. J. Pharmacol. Exp. Ther. (1997) 282(3):1305-1311.
5. PHILIPS MR: Methotrexate and ras methylation: a new trick for an old drug? Sci. STKE (2004) 225:13-23.
6. WINTER-VANN AM, BARON RA, WONG W et al.: A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc. Natl. Acad. Sci. USA (2005) 102(12):4336-4341.
7. CHU E, MOTA AC, FOGARASI MC: Antimetabolites. In: CANCER. Principles and practice of oncology. De Vita Jr VT, Hellmann S, Rosenberg SA (Eds), Lippincott W&W, Philadelphia, USA (2001):388-415.
8. WEI WH, FOUNTAIN M, MACDA D et al.: Gadolinium texaphyrin-methotrexate conjugates. Towards improved cancer chemotherapeutic agents. Org. Biomol. Chem. (2005) 3(18):3290-3296.
9. BANERJEE D, MAYER-KUCKUK P, CAPIAUX G, BUDAK-ALPDOGAN T, GORLICK R, BERTINO JR: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim. Biophys. Acta (2002) 1587:164-173.
10. BLAKLEY RL, SORRENTINO BP: In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: potential for clinical application. Hum. Mutat. (1998) 11:259-263.
11. BOSSON G: Reduced folate carrier: biochemistry and molecular biology of the normal and methotrexate-resistant cell. Br. J. Biomed. Sci. (2003) 60(2):117-129.
12. COLE PD, KAMEN BA, GORLICK R et al.: Effects of overexpression of γ-glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res. (2001) 61: 4599-4604.
13. ALBERTSON DG, COLLINS C, MCCORMICK F, GRAY JW: Chromosome aberrations in solid tumors. Nat. Genet. (2003) 34:369-376.
14. MORALES C, RIBAS M, AIZA C, PEINADO MA: Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells. Oncogene (2005) Epub ahead of print.
15. LIN JT, CASHMORE AR, BAKER MA et al.: Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. Cancer Res. (1987) 47:609-616.
16. BENNET CL, ODDONE E, MATCHAR D: Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers? Clin. Perform Qual. Health Care (1995) 3(3):156-164.
17. TAKIMOTO CH, ALLEGRA CJ: New antifolates in clinical development. Oncology (1995) 9(7):649-656.
18. MACHIAVELLI MR, SALUM G, PÉREZ JE et al.: Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. Am. J. Clin. Oncol. (2004) 27(2):149-154.
19. BLACKLEDGE G: New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). Br. J. Cancer (1998) 77(S2):29-37.
20. BAAS P, ARDIZZONI A, GROSSI F et al.: The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma: an EORTC Phase II study (08992). Eur. J. Cancer (2003) 39:353-357.
21. FIZAZI K, DOUBRE H, LE CHEVALIER T et al.: Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a Phase II study. J. Clin. Oncol. (2003) 21:349-354.
22. VAN MEERBECK JP, GAFAAR R, MANEGOLD C et al.: Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. (2005) 23:6881-6889.
23. CUNNINGHAM D, ZALCBERG JR, PATH U et al.: 'Tomudex' (ZD1694) - results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur. J. Cancer (1995) 31:1945-1954.
24. COCCONI G, CUNNINGHAM D, VAN CUTSEM E et al.: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J. Clin. Oncol. (1998) 16(9):2943-2952.
25. FELIU J, MEL JR, CAMPS C et al.: Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen. Eur. J. Cancer (2002) 38:1204-1211.
26. ADJEI AA: Pharmacology and mechanism of action of pemetrexed. Clin. Lung Cancer (2004) (S2):S51-S55.
27. ADJEI AA: Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev. Anticancer Ther. (2003) 3:89-100.
28. ZHAO R, ZHANG S, HANSCOM M, CHATTOPADHYAY S, GOLDMAN D: Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin. Cancer Res. (2005) 11:1294-1301.
29. ZHAO R, HANSCOM M, CHATTOPADHYAY S, GOLDMAN ID: Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier; association with the presence of a secondary transport pathway. Cancer Res. (2004) 64:3313-3319.
30. NIYIKIZA C, BAKER SD, SEITZ DE et al.: Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. (2002) 1:545-552.
31. WORZALLA JF, SHIH C, SCHULTZ RM: Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anti-Cancer Res. (1998) 18(5A):3235-3239.
32. GIOVANNETTI E, MEY V, NANNIZZI S et al.: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol. Pharmacol. (2005) 68(1):110-118.
33. VOGELZANG NJ, RUSTHOVEN JJ, SYMANOWSKI J et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. (2003) 21(14):2636-2644.
34. HANNA N, SHEPHERD FA, FOSSELLA FW et al.: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. (2004) 22:1589-1597.
35. SCAGLIOTTI GV, SHIN DM, KINDLER HL et al.: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. (2003) 21:1556-1561.
36. PACKAGE INSERT: Alimta (pemetrexed). Indianapolis, IN, USA. Eli Lilly, (August 2004).
37. DAI H, CHEN Y, ELMQUIST WF: Distribution of the novel antifolate pemetrexed to the brain. J. Pharmacol. Exp. Ther. (2005) 5:222-229.
38. O'SHAUGHNESSY JA, CLARK RS, BLUM JL et al.: Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin. Breast Cancer (2005) 6(2):143-149.
39. CLARKE SJ, ABRATT R, GOEDHALS L et al.: Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann. Oncol. (2002) 13:737-741.
40. RUSTHOVEN JJ, EISENHAUER E, BUTTS C et al.: Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a Phase II study. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (1999) 17:1194-1199.
41. SHEPHERD FA, DANCEY J, ARNOLD A et al.: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer (2001) 92:595-600.
42. MANEGOLD C, GATZEMEIER U, VON PAWEL J et al.: Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter Phase II trial. Ann. Oncol. (2000) 11:435-440.
43. BAYES M, RABASSEDA X, PROUS JR: Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. (2003) 25(6):483-506.
44. SIROTNAK FM, DEGRAW JI, COLWELL WT, PIPER JR: A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother. Pharmacol. (1998) 42:313-318.
45. KRUG LM, AZZOLI CG, KRIS MG et al.: 10-Propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin. Cancer Res. (2003) 9:2072-2078.
46. KHOKHAR NZ, SHE Y, RUSCH V, SIROTNAK FM: Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums. Clin. Cancer Res. (2001) 7:3199-3205.
47. FURY MG, KRUG LM, AZZOLI CG et al.: A Phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer Chemother. Pharmacol. (2005) 31:1-7.
48. GALMARINI CM, MACKEY JR, DUMONTET C: Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. (2002) 3:415-424.
49. FADERL S, GANDHI V, KEATING MJ, JEHA S, PLUNKETT W, KANTARJIAN HM: The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer (2005) 103(10):1985-1995.
50. PUI CH, JEHA S, KIRKPATRICK P: Clofarabine. Nat. Rev. Drug Discov. (2005) 4:S12-S13.
51. PLUNKETT W, HUANG P, SEARCY CE, GANDHI V: Gemcitabine: preclinical pharmacology and mechanisms of action. Semin. Oncol. (1996) 23(S10):3-15.
52. HERTEL LW, BODER GB, KROIN JS et al.: Evaluation of the antitumour activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. (1990) 50:4417-4422.
53. PAVLAKIS N, BELL DR, MILLWARD MJ, LEVI JA: Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer (1997) 80(2):286-291.
54. DE CASTRO J, LORENZO A, MORALES S et al.: Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma. Cancer Chemother. Pharmacol. (2005) 55(2):197-202.
55. MATSUDA A, SASAKI T: Antitumor activity of sugar-modified cytosine nucleosides. Cancer Sci. (2004) 95:105-11.
56. KOIZUMI K, SHIMAMOTO Y, AZUMA A et al.: Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells. Int. J. Mol. Med. (2001) 8:273-278.
57. KAZUNO H, SAKAMOTO K, FUJIOKA A, FUKUSHIMA M, MATSUDA A, SASAKI T: Possible antitumor activity of 1-(3-C-ethynyl-d-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line. Cancer Sci. (2005) 96:295-302.
58. LAMONT EB, SCHILSKY RL: The oral fluoropyrimidines in cancer chemotherapy. Clin. Cancer Res. (1999) 5:2289-2296.
59. KELLY H, GOLDBERG RM: Systemic therapy for metastatic colorectal cancer: current options, current evidence. J. Clin. Oncol. (2005) 23:4553-4560.
60. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. (1998) 16:301-308.
61. THIRION P, MICHIELS S, PIGNON JP et al.: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. (2004) 22(18):3766-75.
62. HURWITZ HI, FEHRENBACHER L, HAINSWORTH JD et al.: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. (2005) 23:3502-3508.
63. MCMURROUGH J, MCLEOD HL: Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br. J. Clin. Pharmacol. (1996) 41:425-427.
64. MCKENDRICK J, COUTSOUVELIS J: Capecitabine: effective oral fluoropyrimidine chemotherapy. Expert Opin. Pharmacother. (2005) 6(7):1231-1239.
65. VAN CUTSEM E, TWELVES C, CASSIDY J et al.: Oral capecitabine compared with intravenous fluoruracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large Phase III study. J. Clin. Oncol. (2001) 19:4097-4106.
66. BERGMAN AM, PINEDO HM, JONGSMA AP et al.: Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem. Pharmacol. (1999) 57(4):397-406.
67. BERGMAN AM, PINEDO HM, PETERS GJ: Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Update (2002) 5:19-33.
68. BERGMAN AM, EIJK PP, RUIZ VAN HAPEREN VW et al.: In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. (2005) 65:9510-9516.
69. JORDHEIM LP, GUITTET O, LEPOIVRE M, GALMARINI CM, DUMONTET C: Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol. Cancer Ther. (2005) 4(8):1268-1276.
70. ALLEN WL, JOHNSTON PG: Role of genomic markers in colorectal cancer treatment. J. Clin. Oncol. (2005) 23:4545-52.
71. JOHNSTON PG, DRAKE JC, TREPEL J et al.: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. (1992) 52:4306-4312.
72. LENZ HJ, DANENBERG KD, LEICHMAN CG et al.: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin. Cancer Res. (1998) 4:1227-1234.
73. SALONGA D, DANENBERG KD, JOHNSON M et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. (2000) 6:1322-1327.
74. FARRUGIA DC, FORD HE, CUNNINGHAM D et al.: Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin. Cancer Res. (2003) 9:792-801.
75. GIBBS D, JACKMAN A, KIRKPATRICK P: Pemetrexed disodium. Nat. Rev. Drug Discov. (2005) 4:S16-S17.
76. BUENO R, APPASANI K, MERCER H, LESTER S, SUGARBAKER D: The α-folate receptor is highly activated in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. (2001) 121(2):225-233.
77. EC 2.7.1.48
78. GENBANK AF236637